Active, Not Recruiting
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084
- Conditions
- Bronchial Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
- Locations
-
- Research Site Shanghai, China